Adjuvanted trivalent influenza vaccine: a randomised controlled trial to determine the kinetics of the functional genomic response in young children. In the 2012 influenza season,…
ADITEC’s first year progress The high impact project Advanced Immunization Technologies (ADITEC) started as an ambitious €30 million EU project to boost vaccine research. During…
Since its creation in 1887, the Institut Pasteur has become famous throughout the world as a symbol of science and French culture. For 120 years,…
The ADITEC project has a special Ethical Review Board (ERB): an independent consultant body of the ethical issues of the project. This Board, which will…
After a rigorous selection process, the MOMP antigen from Chlamydia has been selected as the 3rd model antigen. A list of 36 possible antigens for…
Chlamydia MOMP selected as 3rd Model Antigen So far, within the ADITEC project, the research partners worked with two different antigens in their studies: H56…
SSI is a public enterprise under the Danish Ministry of Health. For more than 100 years SSI’s main task has been to secure the preparedness…
Aditec partner Novartis Vaccines Institute for Global Health (NVGH) organizes, together with University of Siena and Novartis Vaccines Academy, the 3rd Master in Vaccinology and…
The Bill & Melinda Gates Foundation’s TB Vaccine Accelerator Program is requesting applications for projects that will help meet one or both of the following…
Are you a student or post-doc and interested in vaccinology? Vaccines Today has started a contest for fun and creative communication concepts to promote vaccination.…